stockportfolio.pro
Monte Rosa Therapeutics, Inc. (GLUE)
Healthcare · Biotechnology · NasdaqGS
Monte Rosa Therapeutics, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $75.62M | $123.67M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-35.88M | $-73.96M | $-108.50M | $-135.35M | $-72.70M | $-38.63M |
| Net margin | — | — | — | — | -96.1% | -31.2% |
Source: Monte Rosa Therapeutics, Inc. SEC filings (10-K).
Explore 6 years of Monte Rosa Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GLUE in your portfolio →
Monte Rosa Therapeutics, Inc. financial history by metric
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics, Inc. — frequently asked questions
What is Monte Rosa Therapeutics, Inc.'s revenue?
Monte Rosa Therapeutics, Inc. (GLUE) reported revenue of $123.67M for fiscal year 2025, up 63.5% from the prior year, according to its SEC filings.
Is Monte Rosa Therapeutics, Inc. profitable?
No — GLUE reported a net loss of $-38.63M in fiscal 2025.
What is GLUE's P/E ratio?
Monte Rosa Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Monte Rosa Therapeutics, Inc. have?
As of fiscal year 2025, GLUE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Monte Rosa Therapeutics, Inc.'s market cap?
Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of about $1.45B, based on the latest data in our nightly-refreshed cache.
When does Monte Rosa Therapeutics, Inc.'s fiscal year end?
GLUE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Monte Rosa Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.